Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp65592_8k.htm |
EXHIBIT 99.1
Press Release www.shire.com |
 |
Holding(s) in Company
May 6, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1.
Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Shire plc | |||
| 2. Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights | X | |||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | X | |||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | X | |||
| An event changing the breakdown of voting rights | ||||
| Other (please specify): | ||||
| 3.
Full name of person(s) subject to the notification obligation: iii |
Deutsche Bank AG | |||
| 4.
Full name of shareholder(s) (if different from 3.):iv |
Deutsche Bank AG, London Branch Deutsche Bank Securities, Inc. | |||
| 5.
Date of the transaction and date on which the threshold is crossed or reached: v |
02/05/2016 | |||
| 6. Date on which issuer notified: | 05/05/2016 | |||
| 7.
Threshold(s) that is/are crossed or reached: vi, vii |
Above 5% | |||
| 8. Notified details: | |||||||
| A: Voting rights attached to shares viii, ix | |||||||
Class/type of
|
Situation
previous to the triggering transaction |
Resulting situation after the triggering transaction | |||||
| Number of Shares |
Number of Voting Rights |
Number of shares |
Number
of voting rights |
% of voting rights x | |||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||
| JE00B2QKY057 | Below notifiable threshold |
Below notifiable threshold | 28,378,378 | 28,378,378 | 0 | 4.78% | 0 |
| B: Qualifying Financial Instruments | ||||
| Resulting situation after the triggering transaction | ||||
| Type
of financial instrument |
Expiration date xiii |
Exercise/
Conversion Period xiv |
Number
of voting rights that may be acquired if the instrument is exercised/ converted. |
%
of voting rights |
Right to Recall Call Option |
16-Dec-16 |
267,285 100,000 |
0.05% 0.02% | |
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
| Resulting situation after the triggering transaction | ||||||
| Type
of financial instrument |
Exercise price | Expiration date xvii | Exercise/ Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx | |
| Swaps | 03-May-17 | 1,390,992 | Nominal | Delta | ||
| 0.23% | 0.23% | |||||
| Total (A+B+C) | |
| Number of voting rights | Percentage of voting rights |
| 30,136,655 | 5.08% |
| 9.
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
Deutsche Bank AG, London Branch 2.29% Deutsche Bank Securities, Inc. 2.79% | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | ||
| 11.
Number of voting rights proxy holder will cease to hold: |
||
| 12.
Date on which proxy holder will cease to hold voting rights: |
||
| 13. Additional information: |
| |
| 14. Contact name: | Stacy Otieno | |
| 15. Contact telephone number: | 02075476268 | |
For further information please contact:
| Investor Relations | |||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com